A previously undetected BRAF p.V600E mutation was emblematic of the clinical utility of this approach in a patient with a liver undifferentiated embryonal sarcoma responsive to BRAF/MEK inhibition. The gene discussed is MAP2K7; the disease is undifferentiated (embryonal) sarcoma.